eyepoint - EYPT
EYPT
Close Chg Chg %
15.92 0.49 3.08%
Open Market
16.41
+0.49 (3.08%)
Volume: 520.29K
Last Updated:
Jan 15, 2026, 11:02 AM EDT
Company Overview: eyepoint - EYPT
EYPT Key Data
| Open $17.16 | Day Range 16.02 - 17.60 |
| 52 Week Range 3.91 - 19.01 | Market Cap $1.32B |
| Shares Outstanding 82.79M | Public Float 73.10M |
| Beta 1.64 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.99 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.07M |
EYPT Performance
| 1 Week | -1.85% | ||
| 1 Month | -0.38% | ||
| 3 Months | 36.97% | ||
| 1 Year | 112.97% | ||
| 5 Years | 45.88% |
EYPT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
About eyepoint - EYPT
EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
EYPT At a Glance
EyePoint Plc
480 Pleasant Street
Watertown, Massachusetts 02472
| Phone | 1-617-926-5000 | Revenue | 43.27M | |
| Industry | Pharmaceuticals: Major | Net Income | -130,870,000.00 | |
| Sector | Health Technology | Employees | 165 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
EYPT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.692 |
| Price to Book Ratio | 1.511 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.496 |
| Enterprise Value to Sales | 1.655 |
| Total Debt to Enterprise Value | 0.323 |
EYPT Efficiency
| Revenue/Employee | 262,260.606 |
| Income Per Employee | -793,151.515 |
| Receivables Turnover | 71.29 |
| Total Asset Turnover | 0.112 |
EYPT Liquidity
| Current Ratio | 7.815 |
| Quick Ratio | 7.768 |
| Cash Ratio | 7.562 |
EYPT Profitability
| Gross Margin | 91.422 |
| Operating Margin | -337.055 |
| Pretax Margin | -302.221 |
| Net Margin | -302.429 |
| Return on Assets | -33.832 |
| Return on Equity | -43.419 |
| Return on Total Capital | -36.393 |
| Return on Invested Capital | -41.573 |
EYPT Capital Structure
| Total Debt to Total Equity | 6.866 |
| Total Debt to Total Capital | 6.425 |
| Total Debt to Total Assets | 5.521 |
| Long-Term Debt to Equity | 6.496 |
| Long-Term Debt to Total Capital | 6.078 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Eyepoint - EYPT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 36.94M | 41.40M | 46.02M | 43.27M | |
Sales Growth
| +7.27% | +12.09% | +11.14% | -5.97% | |
Cost of Goods Sold (COGS) incl D&A
| 10.64M | 10.38M | 4.63M | 3.71M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.77M | 2.45M | 464.00K | 1.54M | |
Depreciation
| 311.00K | 396.00K | 464.00K | 1.54M | |
Amortization of Intangibles
| - | - | 2.46M | 2.05M | - |
COGS Growth
| +28.40% | -2.45% | -55.36% | -19.86% | |
Gross Income
| 26.30M | 31.03M | 41.39M | 39.56M | |
Gross Income Growth
| +0.57% | +17.97% | +33.38% | -4.41% | |
Gross Profit Margin
| +71.20% | +74.94% | +89.93% | +91.42% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 81.58M | 109.97M | 115.05M | 185.41M | |
Research & Development
| 28.50M | 49.64M | 64.36M | 132.93M | |
Other SG&A
| 53.08M | 60.32M | 50.69M | 52.49M | |
SGA Growth
| +28.58% | +34.80% | +4.62% | +61.16% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (2.06M) | 22.26M | 2.75M | |
EBIT after Unusual Expense
| (53.21M) | (101.20M) | (76.41M) | (145.85M) | |
Non Operating Income/Expense
| 292.00K | 2.13M | 6.95M | 15.09M | |
Non-Operating Interest Income
| 292.00K | 2.13M | 6.95M | 15.09M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 5.50M | 3.19M | 1.25M | 14.00K | |
Interest Expense Growth
| -24.24% | -42.00% | -60.90% | -98.88% | |
Gross Interest Expense
| 5.50M | 3.19M | 1.25M | 14.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (58.42M) | (102.25M) | (70.71M) | (130.78M) | |
Pretax Income Growth
| -28.69% | -75.04% | +30.85% | -84.95% | |
Pretax Margin
| -158.14% | -246.97% | -153.66% | -302.22% | |
Income Tax
| - | - | 83.00K | 90.00K | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (58.42M) | (102.25M) | (70.80M) | (130.87M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (58.42M) | (102.25M) | (70.80M) | (130.87M) | |
Net Income Growth
| -28.69% | -75.04% | +30.77% | -84.86% | |
Net Margin Growth
| -158.14% | -246.97% | -153.84% | -302.43% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (58.42M) | (102.25M) | (70.80M) | (130.87M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (58.42M) | (102.25M) | (70.80M) | (130.87M) | |
EPS (Basic)
| -2.0313 | -2.7402 | -1.8197 | -2.3246 | |
EPS (Basic) Growth
| +42.56% | -34.90% | +33.59% | -27.75% | |
Basic Shares Outstanding
| 28.76M | 37.32M | 38.90M | 56.30M | |
EPS (Diluted)
| -2.0313 | -2.7402 | -1.8197 | -2.3246 | |
EPS (Diluted) Growth
| +42.56% | -34.90% | +33.59% | -27.75% | |
Diluted Shares Outstanding
| 28.76M | 37.32M | 38.90M | 56.30M | |
EBITDA
| (52.51M) | (76.49M) | (73.20M) | (144.31M) | |
EBITDA Growth
| -51.57% | -45.69% | +4.31% | -97.16% | |
EBITDA Margin
| -142.14% | -184.75% | -159.06% | -333.50% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 36.083 | |
| Number of Ratings | 12 | Current Quarters Estimate | -0.724 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -2.91 | |
| Last Quarter’s Earnings | -0.72 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.033 | Next Fiscal Year Estimate | -2.551 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 12 | 10 |
| Mean Estimate | -0.72 | -0.73 | -2.91 | -2.55 |
| High Estimates | -0.65 | -0.65 | -2.21 | -1.15 |
| Low Estimate | -0.80 | -0.80 | -3.50 | -3.57 |
| Coefficient of Variance | -7.48 | -7.69 | -13.03 | -33.49 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 11 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Eyepoint - EYPT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Eyepoint - EYPT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 8, 2026 | Nancy Sue Lurker Director | 12,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Reginald J. Sanders Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Karen L. Zaderej Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 15,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 39,333 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 126,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 63,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 81,054 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.43 per share | 1,412,771.22 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 85,457 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 70,457 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.48 per share | 1,231,588.36 |
| Jan 8, 2026 | George O. Elston Chief Financial Officer | 76,781 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 74,965 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Nancy Sue Lurker Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Nancy Sue Lurker Director | 219,213 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 30,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 130,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 331,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 165,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 67,013 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.43 per share | 1,168,036.59 |
| Jan 8, 2026 | Jay S. Duker President and CEO; Director | 81,518 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |